Origin and therapy for hypertriglyceridaemia in type 2 diabetes

    Research output: Contribution to journalReview article

    397 Downloads (Pure)

    Abstract

    Hypertriglyceridaemia (HTG) is a risk factor for cardiovascular disease (CVD) in type 2 diabetes and is caused by the interaction of genes and non-genetic factors, specifically poor glycaemic control and obesity. In spite of statin treatment, residual risk of CVD remains high in type 2 diabetes, and this may relate to HTG and atherogenic dyslipidemia. Treatment of HTG emphasises correcting secondary factors and adverse lifestyles, in particular, diet and exercise. Pharmacotherapy is also required in most type 2 diabetic patients. Statins are the first-line therapy to achieve recommended therapeutic targets of plasma low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol. Fibrates, ezetimibe and n-3 fatty acids are adjunctive treatment options for residual and persistent HTG. Evidence for the use of niacin has been challenged by non-significant CVD outcomes in two recent large clinical trials. Further investigation is required to clarify the use of incretin-based therapies for HTG in type 2 diabetes. Extreme HTG, with risk of pancreatitis, may require insulin infusion therapy or apheresis. New therapies targeting HTG in diabetes need to be tested in clinical endpoint trials. The purpose of this review is to examine the current evidence and provide practical guidance on the management of HTG in type 2 diabetes.

    Original languageEnglish
    Pages (from-to)165-175
    Number of pages11
    JournalWORLD JOURNAL OF DIABETES
    Volume5
    Issue number2
    DOIs
    Publication statusPublished - 15 Apr 2014

    Fingerprint Dive into the research topics of 'Origin and therapy for hypertriglyceridaemia in type 2 diabetes'. Together they form a unique fingerprint.

  • Cite this